



Guidelines for Preventive Health Maintenance of Sickle Cell Patients

Health Maintenance Recommendations			
Patient/Parent Education	<ul style="list-style-type: none"> Physical assessment skills (e.g. palpation of spleen) How to avoid vaso-occlusive complications and how to treat pain When to administer prophylactic antibiotics Importance of taking prompt action at the first sign of fever and other signs of infection 		
Routine Clinical Laboratory Evaluations in children	Test	Age	Frequency
	CBC w/ WBC differential, reticulocyte count	<ul style="list-style-type: none"> 3 mo—24 mo >24 mo 	<ul style="list-style-type: none"> every 3 months every 6 months
	Percent Hb F	<ul style="list-style-type: none"> 6 mo —24 mo >24 mo 	<ul style="list-style-type: none"> every 6 months annually (may vary based on clinical course)
	Renal function (creatinine, BUN, urinalysis)	<ul style="list-style-type: none"> ≥ 12 mos 	<ul style="list-style-type: none"> annually
	Hepatobiliary function (ALT, fractionated bili)	<ul style="list-style-type: none"> ≥ 12 mos 	<ul style="list-style-type: none"> annually
	Pulmonary function (transcutaneous O ₂ saturation)	<ul style="list-style-type: none"> ≥ 12 mos 	<ul style="list-style-type: none"> every 6 mo (may vary based on clinical course)
Pneumococcal Immunization in children	Previously Unvaccinated Children w/ Sickle Cell Disease		
	Product	1st Dose	Primary Series
	PCV7 (Prevnar)	2-6 mo	3 doses 6-8 wk apart
		7-11 mo	2 doses 6-8 wk apart
		≥ 12 mos	2 doses 6-8 wk apart
	PPV23 (Pneumovax)	≥ 24 mo	1 dose at least 6-8 wk after last dose of PCV7 dose
			1 dose, 3-5 yr after 1 st PPV23 dose
	Previously Vaccinated Children w/ Sickle Cell Disease		
	Age	Previous Dose	Recommended
	12-23 mo	Incomplete primary PCV7	2 doses PCV7, 6-8 wk apart
≥ 24 mo	4 doses PCV7	1 st dose PPV23, 6-8 wk after PCV7 2 nd PPV23 dose, 3-5 yr after 1 st PPV23	
	1-3 doses PPV7 (before 24 mo of age)	1 dose PPV7 1 st dose PPV23, 6-8 wk after PCV7 2 nd PPV23 dose, 3-5 yr after 1 st PPV23	
	1 dose PPV23	2 doses PCV7, 6-8 wk apart, 1 st dose given at least 8 wk after PPV23 dose; 2 nd PPV23 dose, 3-5 yr after 1 st PPV23	
Penicillin Prophylaxis in children	<p>Penicillin is given twice daily from as early as 2 months of age, a treatment supported by the hallmark Penicillin Prophylaxis Studies of the 1980s</p> <ul style="list-style-type: none"> Penicillin VK: 125 mg by mouth twice daily for those under 3 years of age Penicillin VK: 250 mg twice daily for those 3 and older (up to age 5 years old) Alternative to oral is an injection: 1.2 million units of long-acting BicillinTM every 3 weeks For children allergic to penicillin, erythromycin ethyl succinate (20mg/kg) divided into 2 daily doses can provide adequate prophylaxis 		
Evaluation of Fever in children	<ul style="list-style-type: none"> All children with SCD who have a fever (>38.5C or 101F) and other signs of infection (chills, lethargy, irritability, poor feeding, vomiting) should be evaluated promptly. Instruct parents not to treat with antipyretics at home and wait for recurrence or persistence of fever. Child should be evaluated immediately upon presentation of s/s of infection 		
Anemia Prevention- in children and adults	<ul style="list-style-type: none"> In surgical settings, simple transfusions to increase hemoglobin levels to 10g/dl are as good as or safer than aggressive transfusions to reduce sickle cell hemoglobin (Hb S) levels to below 30 percent. Transfusions to maintain a hematocrit of more than 36 percent do not reduce complications of <u>pregnancy</u> Transfusions to reduce Hb S levels to below 30 percent prevent strokes in <u>children</u> with high central nervous system blood flow [evidence from the Stroke Prevention Trial in Sickle Cell Anemia (STOP I)]. 		
Crisis Prevention in Adults	<ul style="list-style-type: none"> Hydroxyurea decreases crisis in patients with severe sickle cell disease [evidence from the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) trial]. 		